Elevated levels of adiponectin associated with major adverse cardiovascular and cerebrovascular events and mortality risk in ischemic stroke

Table 3 Multivariate Cox analysis of MACCE and mortality in stroke patients during 3-year follow-up

Variable	MACCE^a		Mortality^b
Variable	HR (95%CI)	P	HR (95%CI)	P
Age (increase per unit)	1.08 (1.01–1.16)	0.009	1.11 (1.04–1.19)	0.006
Sex (female vs. male)	1.43 (0.90–2.15)	0.16	–
BMI (≥ 30 vs. < 30 kg/m2)	1.16 (1.04–1.26)	0.018	1.18 (1.03–1.29)	0.016
Diabetes mellitus (yes vs. no)	1.11 (1.02–1.32)	0.042	–
Atrial fibrillation (yes vs. no)	1.48 (0.92–2.67)	0.063	–
Previous CVD events (yes vs. no)	1.12 (1.02–1.25)	0.016	1.15 (0.99–1.38)	0.15
NIHSS (increase per unit)	1.14 (1.07–1.23)	< 0.001	1.16 (1.09–1.24)	< 0.001
Stroke syndrome (TACS vs. other)	2.25 (0.75–4.32)	0.38	2.56 (0.68–4.76)	0.43
Stroke subtype (Cardioembolic vs. other)	1.07 (0.86–2.14)	0.26	1.14 (0.97–1.89)	0.18
Acute treatment (no vs. yes)	3.01 (1.98–4.05)	< 0.001	3.75 (2.96–4.49)	< 0.001
Glucose (increase per unit)	1.07 (0.98–1.25)	0.15	1.09 (1.00–1.23)	0.076
eGFR (increase per unit)	1.02 (0.93–1.43)	0.13	1.03 (1.00–1.11)	0.045
CRP (increase per unit)	1.03 (1.00–1.09)	0.015	1.05 (1.01–1.11)	0.011
Copeptin (Q4 vs. Q1-3)	2.98 (1.55–4.07)	0.001	3.65 (2.12–5.05)	< 0.001
NT-pro BNP (Q4 vs. Q1-3)	2.05 (1.21–3.39)	0.009	3.03 (1.87–4.23)	0.003
Adiponectin (increase per unit)	1.13 (1.06–1.19)	< 0.001	1.17 (1.11–1.24)	< 0.001

HR Hazard ratio, CI confidence interval, BMI body mass index, NIHSS National Institutes of Health Stroke Scale, CRP C-reactive protein, NT-proBNP N-terminal fragment of precursor of B-type natriuretic peptide, TACS total anterior circulation syndrome, GFR glomerular filtration rate, CVD cardiovascular disease, MACCE major adverse cardiovascular and cerebrovascular events
^aAdjusted for age, sex (female vs. male), BMI (yes vs. no), Diabetes mellitus (yes vs. no), Atrial fibrillation (yes vs. no), Previous CVD events (yes vs. no), NHISS, Stroke syndrome (TACS vs. other), Stroke subtype (Cardioembolic vs. other), Acute treatment (no vs. yes), serum levels of Glucose, CRP, eGFR, Copeptin, NT-ProBNP and Adiponectin. MACCE was defined as CVD death, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization by percutaneous coronary intervention or coronary artery bypass grafting
^bAdjusted for age, BMI (yes vs. no), Previous CVD events (yes vs. no), NHISS, Stroke syndrome (TACS vs. other), Stroke subtype (Cardioembolic vs. other), Acute treatment (no vs. yes), serum levels of Glucose, CRP, eGFR, Copeptin, NT-ProBNP and Adiponectin

ISSN: 1475-2840